National Bank of Greece completes buyback of over 249,000 shares in August

Pavlos Mylonas CEO
Pavlos Mylonas CEO
0Comments

National Bank of Greece S.A. has announced the purchase of 249,305 of its own common shares between August 18 and August 22, 2025. The shares were bought on the Athens Stock Exchange at a weighted average price of €12.8827 per share, totaling €3,211,725.94.

The transactions were carried out as part of the first tranche of a share buyback program approved by shareholders at the Annual General Meeting on May 30, 2025. The program also received approval from the Single Supervisory Mechanism (SSM) of the European Central Bank on May 28, 2025.

The bank provided details for each day’s purchases during this period:
– On August 18: 50,000 shares at €13.0502 each.
– On August 19: 50,000 shares at €12.9681 each.
– On August 20: 50,000 shares at €12.7843 each.
– On August 21: 50,000 shares at €12.7984 each.
– On August 22: 49,305 shares at €12.8116 each.

According to the announcement, “it is noted that in accordance with the resolutions of above-mentioned Annual General Meeting, the Bank intends to proceed with a subsequent cancellation of the above acquired own shares, in accordance with the relevant provisions regarding the time frame for the cancellation of Law 4548/2018.”

Following these transactions, National Bank of Greece S.A. now holds directly a total of 6,931,557 own shares—representing approximately 0.76% of its share capital.

The announcement was made in line with (EU) Regulation No 596/2014 and other applicable regulations governing such transactions.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.